查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014715

心臟泵設備市場：按設備類型、應用、最終用戶和銷售管道分類 - 全球市場預測 2026-2032

Heart Pump Device Market by Device Category, Application, End User, Sales Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，心臟幫浦設備市場價值將達到 64.6 億美元，到 2026 年將成長至 75.5 億美元，到 2032 年將達到 196.4 億美元，複合年成長率為 17.21%。

主要市場統計數據
基準年 2025 64.6億美元
預計年份：2026年 75.5億美元
預測年份 2032 196.4億美元
複合年成長率 (%) 17.21%

一個全面的策略實施方案，概述了正在重塑機械循環支援的臨床需求、技術進步和機構壓力。

本報告首先清楚闡述了在日益成長的臨床需求和不斷發展的技術生態系統背景下，為何必須將策略重點放在心臟幫浦設備上。機械循環支援技術的進步正在改變患者的治療路徑，使更多患者能夠延長壽命並改善功能狀態，同時也對設備的安全性、耐用性和與數位化醫療平台的整合提出了新的要求。臨床醫生、醫院管理者和設備製造商正在應對臨床需求、監管審查和供應鏈複雜性之間的複雜互動，所有這些因素共同決定了短期內的商業環境。

對技術創新、不斷發展的醫療保健服務以及對證據的需求進行深入分析，這些因素正在重新定義心臟幫浦治療領域的競爭優勢。

心臟幫浦裝置領域正經歷一場變革，其驅動力來自於技術突破、不斷演進的醫療服務模式以及對長期治療效果日益成長的重視。微創植入技術和更緊湊的泵體結構擴大了適用患者群體，同時降低了手術全期風險，從而促進了治療模式從單純住院手術向門診和以護理為基礎的治療模式的轉變。同時，植入式感測器和遠端監測平台的普及實現了持續的生理監測，有助於早期療育並降低再入院率。這些都是醫療體系至關重要的績效指標。

對近期美國關稅趨勢如何重塑心臟幫浦設備整個價值鏈的供應鏈、籌資策略和商業性模式進行詳細評估。

在目前政策週期內，美國關稅的徵收和調整對心臟泵設備生態系統產生了多方面的影響，波及零件採購決策、供應商關係和成本結構，但並未對臨床應用趨勢產生統一影響。尤其值得注意的是，針對主要子組件和原料的關稅迫使製造商重新評估供應商多元化策略，加快替代供應商的認證，並考慮採用合約避險策略來保護利潤率。對於海外生產設施集中的公司而言，此類關稅體系促使它們考慮近岸外包以維持供應連續性、關鍵子組件的垂直整合或策略性庫存緩衝。

整合策略性細分，明確界定醫療設備類別、醫療保健環境、銷售管道和應用領域在臨床、商業和製造優先事項上的差異。

細分市場分析揭示了醫療設備類別、醫療機構、銷售管道和臨床應用的不同策略重點，這些因素共同構成了多種成長和專業化路徑。在器械類別中，人工心臟和心室輔助裝置之間存在著明顯的區別。後者可進一步細分為雙心室輔助裝置、左心室輔助裝置和右心室輔助裝置，每種裝置都有其獨特的技術複雜性、臨床工作流程和售後服務要求。這些類別內部的差異會影響製造業的複雜性和售後市場需求。與左心室系統相比，右心室輔助裝置通常具有不同的血流動力學控制和尺寸限制。

對美洲、歐洲、中東、非洲和亞太地區在監管、報銷和醫療保健服務要求方面的差異進行詳細的區域分析。

區域趨勢呈現出不同的機會和法規環境，對美洲、歐洲、中東、非洲和亞太地區的商業化和商業策略產生重大影響。在美洲，成熟的三級醫療網路和先進的報銷機制促進了尖端機械循環支援解決方案的採用，從而推動了市場需求。然而，採購週期和醫院預算限制仍然要求提供令人信服的價值提案和可靠的臨床證據，以支持資本投資決策。

一項前瞻性的競爭評估，重點闡述了產品創新、臨床證據生態系統和生命週期服務如何決定機械循環支援設備領域的領導地位。

心臟幫浦設備生態系統的競爭格局日益取決於企業能否將臨床證據、生產規模和卓越的售後服務整合為連貫的價值提案。主要企業持續投資於迭代式設備改進、感測器驅動的監測和遠端系統管理平台，以減輕臨床醫生的負擔並改善患者的治療效果。同時，新興參與企業正利用創新材料科學、小型化和軟體主導的控制架構，挑戰關於設備設計和患者選擇的傳統觀念。

為領導者提供切實可行的策略建議，以協調臨床證據產生、供應鏈韌性和服務創新，從而加速推廣應用並保持競爭優勢。

產業領導者應採取組合策略，平衡短期商業化與對永續能力的投資，從而降低風險並提升臨床價值。應優先產生可操作的臨床證據，不僅要證明設備性能，還要證明其能夠減少下游醫療資源的消耗並改善患者報告的療效。將遠端監測數據和標準化療效指標納入與保險公司的溝通中，可以增強報銷優勢並縮短採購決策週期。

採用嚴謹的混合方法研究途徑，結合臨床醫師訪談、監管分析、供應鏈映射和證據檢驗驗證，以檢驗策略結論。

本分析所依據的研究採用了一種混合方法，整合了對關鍵相關人員的訪談、臨床文獻回顧、監管申報分析以及供應鏈圖譜繪製，以確保研究結果得到可靠的三角檢驗。關鍵訪談對象涵蓋了眾多專家，包括心臟外科醫師、心臟衰竭循環系統、採購經理、生產主管和臨床試驗負責人，旨在全面了解各種醫療機構的實際情況和策略重點。此外，研究人員還對同行評審的臨床研究、註冊數據和特定器械的上市後報告進行了系統性回顧，從而將器械性能說明與已發表的證據進行比對，進一步補充了這些定性見解。

簡明扼要地總結了創新、證據產生和運作韌性如何共同決定機械循環支援設備的成功。

總而言之，心臟幫浦設備產業正處於轉折點，臨床創新、醫療服務模式轉型和營運韌性必須協同運作，才能實現更廣泛的應用並造福患者。儘管技術進步正在拓展適應症範圍並推動其在新的醫療環境中部署，但商業化的成功取決於能否展現長期價值、管理複雜的價值鏈，以及整合能夠支持患者和醫療服務提供者貫穿整個醫療服務鏈的服務。價格壓力和區域差異凸顯了供應多元化和在地化策略的重要性，而市場區隔洞察則揭示了產品需求和打入市場策略的顯著差異。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依設備類別分類的心臟幫浦設備市場

  • 人工心臟
  • 心室輔助裝置
    • 雙心室輔助裝置
    • 左心室輔助裝置
    • 右心室輔助裝置

第9章：心臟幫浦設備市場：依應用分類

  • 移植前的過渡治療
  • 最終治療
    • 成人版
    • 兒童

第10章：心臟幫浦設備市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第11章：心臟幫浦設備市場：依銷售管道分類

  • 直銷
  • 透過分銷商銷售

第12章 心臟幫浦設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：心臟幫浦設備市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：心臟幫浦設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國心臟幫浦設備市場

第16章：中國心臟幫浦設備市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • BiVACOR, Inc.
  • Calon Cardio-Technology Ltd.
  • CardiacAssist, Inc.
  • CH Biomedical, Inc.
  • Cirtec Medical Systems, Inc.
  • CorWave SA
  • Evaheart, Inc.
  • FineHeart SA
  • Getinge AB
  • Jarvik Heart, Inc.
  • Leviticus Cardio Ltd.
  • LivaNova plc
  • Medtronic plc
  • NuPulseCV, Inc.
  • ReliantHeart, Inc.
  • SynCardia Systems, LLC
  • Terumo Corporation
Product Code: MRR-437E9896A563

The Heart Pump Device Market was valued at USD 6.46 billion in 2025 and is projected to grow to USD 7.55 billion in 2026, with a CAGR of 17.21%, reaching USD 19.64 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.46 billion
Estimated Year [2026] USD 7.55 billion
Forecast Year [2032] USD 19.64 billion
CAGR (%) 17.21%

A comprehensive strategic introduction outlining the clinical imperatives, technological advances, and systemic pressures reshaping mechanical circulatory support delivery

This report opens with a clear framing of why heart pump devices warrant concentrated strategic attention amid intensifying clinical demand and evolving technology ecosystems. Advances in mechanical circulatory support have shifted patient pathways, enabling more patients to live longer and with improved functional status, while simultaneously creating new imperatives for device safety, durability, and integration with digital care platforms. Clinicians, hospital administrators, and device manufacturers are navigating a confluence of clinical need, regulatory scrutiny, and supply chain complexity that together define the near-term operational landscape.

While the clinical rationale for devices such as total artificial hearts and ventricular assist devices is well established, the contemporary market is being reshaped by innovations in miniaturization, biocompatible materials, sensor-enabled controls, and telemonitoring. These technological improvements are extending indications and enabling greater use in outpatient and ambulatory surgical center settings. Moreover, the interplay between payer expectations and evidence generation is driving manufacturers to prioritize real-world performance data and value-based outcomes. Consequently, strategic planning must integrate clinical pathways, reimbursement strategies, and manufacturing scalability to convert innovation into durable commercial success.

As a result, stakeholders should adopt a patient- and system-centered view that anticipates shifting treatment locations, converging device and software ecosystems, and heightened expectations for post-implant follow-up. This introduction establishes the context for subsequent sections by highlighting the core forces-clinical need, technological progress, regulatory dynamics, and supply chain pressures-that together shape strategic choices for all participants in the heart pump device ecosystem.

An incisive examination of technological innovation, care delivery evolution, and evidence demands that are redefining competitive advantage in heart pump therapy

The landscape for heart pump devices is undergoing transformative shifts driven by a combination of technological breakthroughs, evolving care delivery models, and increasing emphasis on long-term outcomes. Minimally invasive implantation techniques and more compact pump architectures are broadening candidate populations while reducing perioperative risk, which in turn supports a transition from exclusively inpatient procedures toward ambulatory and outpatient settings. Concurrently, the proliferation of embedded sensors and remote monitoring platforms is enabling continuous physiologic surveillance, facilitating early intervention and reducing readmission rates, which are critical performance indicators for health systems.

Equally consequential is the maturation of destination therapy as a sustained treatment pathway rather than a bridge to transplant. As device durability improves and biocompatibility advances lower complication rates, clinicians are more likely to consider mechanical support for patients who are not transplant candidates. This shift increases the need for robust long-term management models, including remote telemetry, structured anticoagulation clinics, and integrated rehabilitation programs. Regulatory pathways are adapting to accommodate incremental device updates and software-driven features, requiring manufacturers to align development roadmaps with post-market surveillance obligations and real-world evidence generation.

In parallel, stakeholder expectations around total cost of care are prompting device makers to demonstrate value beyond device performance. Hospitals and payers increasingly demand data that correlate device use with reductions in length of stay, rehospitalizations, and downstream costs. Therefore, strategic differentiation will hinge on the ability to deliver clinical efficacy alongside demonstrable health-economic benefits. Taken together, these transformative shifts redefine competitive advantage as the intersection of compelling clinical outcomes, robust evidence generation, and seamless integration into evolving care pathways.

A detailed assessment of how recent United States tariff dynamics are reshaping supply chains, sourcing strategies, and commercial approaches across the heart pump device value chain

The imposition and adjustment of tariffs in the United States during the current policy cycle have imposed layered effects on the heart pump device ecosystem, influencing component sourcing decisions, supplier relationships, and cost structures without uniformly altering clinical adoption dynamics. Importantly, tariffs that target key subcomponents or raw materials pressure manufacturers to reassess supplier diversification, accelerate qualification of alternate vendors, and consider contractual hedges that protect margins. For companies with concentrated offshore manufacturing footprints, such tariff regimes stimulate deliberations about nearshoring, vertical integration of critical subassemblies, or strategic inventory buffering to maintain supply continuity.

These trade-related frictions also have downstream implications for distribution strategies and service models. Hospitals and ambulatory centers may experience phased adjustments in procurement pricing that influence capital purchase cycles and comparative evaluations across therapeutic options. To preserve adoption momentum, device companies are increasingly implementing bundled-service propositions and extended warranties that absorb some cost volatility for buyers, while simultaneously seeking operational efficiencies in manufacturing and logistics. Furthermore, tariffs can complicate collaborative arrangements with contract manufacturers and foreign research partners by introducing administrative and compliance overhead that lengthens time-to-market for incremental product updates.

Regulatory and payer stakeholders react to cost dynamics as well; sustained increases in equipment and consumable prices can prompt closer scrutiny of reimbursement pathways and utilization criteria. Consequently, navigating tariff impacts requires a multifaceted response that combines supply-chain resilience, pricing strategy refinement, proactive stakeholder communication, and targeted investments in manufacturing agility. In sum, the cumulative tariff effects in the United States during this period have catalyzed a rebalancing of sourcing, production, and commercial tactics across the heart pump device value chain.

A strategic segmentation synthesis that clarifies differentiated clinical, commercial, and manufacturing priorities across device categories, care settings, channels, and applications

Segmentation analysis reveals differentiated strategic priorities across device categories, care settings, sales channels, and clinical applications that together create multiple routes to growth and specialization. Within device category, there is a clear distinction between total artificial hearts and ventricular assist devices; the latter further segments into biventricular, left ventricular, and right ventricular assist devices, each with distinct engineering complexity, clinical workflows, and follow-on service demands. These intra-category distinctions influence manufacturing complexity and aftermarket needs, with right-sided support typically featuring different hemodynamic controls and size constraints compared with left ventricular systems.

End-user segmentation highlights divergent procurement and clinical adoption dynamics between ambulatory surgical centers and hospitals. Hospitals remain the primary locus for advanced implantations due to their intensive care capabilities and multidisciplinary teams, whereas ambulatory surgical centers represent a growing locus for lower-risk procedures as device profiles evolve and perioperative pathways become more streamlined. Sales channel differentiation between direct sales and distributor-led models shapes commercial resource allocation and customer engagement tactics. Direct sales often enable deeper clinical training and tighter integration of service contracts, while distributor sales can provide broader geographic reach and channel moderation for companies without a full sales infrastructure.

Application-based distinctions further refine opportunity sets. The bridge-to-transplant use case requires alignment with transplant center networks and often entails complex patient selection and short-term management protocols. Destination therapy, which is subdivided into adult and pediatric populations, places a premium on long-term device reliability, patient support ecosystems, and life-cycle management programs. Pediatric destination therapy introduces additional regulatory and design considerations related to growth accommodation and long-term biocompatibility. By synthesizing these segmentation lenses, manufacturers and providers can prioritize investments in product design, clinical education, and service models that correspond to the highest strategic fit for their capabilities and market aspirations.

A nuanced regional analysis describing differentiated regulatory, reimbursement, and care delivery imperatives across the Americas, Europe Middle East and Africa, and Asia Pacific

Regional dynamics offer varied opportunity sets and regulatory environments that materially influence commercialization and operational strategies across the Americas, Europe Middle East and Africa, and Asia Pacific. In the Americas, demand drivers are underpinned by established tertiary care networks and advanced reimbursement mechanisms that facilitate the adoption of cutting-edge mechanical circulatory support solutions; however, procurement cycles and hospital budget constraints still require compelling value narratives and robust clinical evidence to support capital investment decisions.

The Europe Middle East and Africa region exhibits heterogeneity in regulatory pathways and health system financing, which necessitates tailored market entry strategies. In Western European markets, established regulatory harmonization and specialized cardiac centers enable focused launches and post-market data collection, while certain Middle Eastern markets present opportunities through government-led modernization programs and private hospital expansion. Across Africa, nascent infrastructure and limited specialist capacity imply longer timelines for adoption, with opportunities often tied to capacity building, training partnerships, and phased technology transfer.

Asia Pacific presents a dual landscape of highly advanced markets alongside rapidly developing care ecosystems. High-income markets within the region adopt innovative device features and digital integration relatively quickly, supported by growing domestic manufacturing capabilities and strategic partnerships. Conversely, emerging markets prioritize affordability, local serviceability, and clinical training; success in these settings often hinges on adaptive pricing strategies, localized clinical education programs, and distributor networks that can support decentralized care delivery. Collectively, these regional distinctions require calibrated go-to-market models that respect local regulatory regimes, reimbursement realities, and clinical capacity, while allowing for scalable operational frameworks that can be adapted as demand and infrastructure evolve.

A forward-looking competitive assessment highlighting how product innovation, clinical evidence ecosystems, and lifecycle services determine leadership in mechanical circulatory support

Competitive dynamics in the heart pump device ecosystem are increasingly defined by the ability to integrate clinical evidence, manufacturing scale, and aftermarket service excellence into a coherent value proposition. Leading organizations continue to invest in iterative device improvements, sensor-enabled monitoring, and remote management platforms that reduce clinician burden and improve patient outcomes. Concurrently, emerging entrants are leveraging disruptive materials science, smaller form factors, and software-driven control architectures to challenge legacy assumptions about device design and patient selection.

Strategic behavior among manufacturers includes horizontal and vertical partnerships, targeted acquisitions to secure component capabilities, and collaborative clinical programs with tertiary centers to accelerate evidence generation. Contract manufacturers and specialist suppliers have become critical strategic partners for firms seeking to scale production while maintaining flexibility to adapt to evolving tariffs and regulatory requirements. Intellectual property portfolios and regulatory filings serve as key differentiators, particularly where novel hemodynamic control algorithms or biocompatible materials confer clinical or operational advantages.

Service and lifecycle management capabilities are a major competitive battleground. Organizations that can bundle device hardware with robust training, remote monitoring, predictive maintenance, and outcome reporting create stickier commercial relationships and more defensible pricing positions. Finally, access to specialized pediatric expertise and evidence tailored to smaller patient cohorts represents a niche where targeted investments can yield durable competitive advantage. Overall, the combination of product differentiation, evidence generation, supply chain resilience, and service excellence will determine which companies lead in both high-acuity hospital markets and emerging ambulatory settings.

Actionable strategic recommendations for leaders to align clinical evidence generation, supply chain resilience, and service innovation to accelerate adoption and sustain competitive advantage

Industry leaders should adopt a portfolio approach that balances near-term commercialization with investments in durable capabilities that reduce risk and increase clinical value. First, prioritize the generation of pragmatic clinical evidence that demonstrates not only device performance but also the capacity to reduce downstream utilization and improve patient-reported outcomes. Integrating remote monitoring data and standardized outcome metrics into payer conversations will strengthen reimbursement positioning and shorten procurement decision cycles.

Second, fortify supply chain resilience by diversifying supplier bases, qualifying secondary sources for critical components, and exploring localized assembly or nearshoring for high-risk subassemblies. These measures mitigate tariff exposure and support faster response to regulatory or pandemic-driven disruptions. Third, design commercial models that reflect the realities of the end-user landscape: invest in direct-sales capabilities and clinical education in high-volume tertiary centers, while building distributor partnerships and adaptive pricing for emerging and cost-sensitive markets.

Fourth, expand service offerings that encompass remote patient management, predictive maintenance, and outcome-focused training programs to create recurring revenue streams and deepen customer relationships. Fifth, pursue targeted pediatric strategies where clinical differentiation and limited competition can justify premium positioning, while ensuring device architectures account for growth and long-term biocompatibility. Finally, engage proactively with regulators and payers to co-develop post-market surveillance frameworks that support iterative improvement while maintaining patient safety. By executing these recommendations in parallel, companies can convert technological innovation into sustainable commercial advantage and system-level value.

A rigorous mixed-methods research approach integrating clinician interviews, regulatory analysis, supply chain mapping, and evidence triangulation to validate strategic conclusions

The research underpinning this analysis draws on a mixed-methods approach that integrates primary stakeholder interviews, clinical literature review, regulatory filing analysis, and supply chain mapping to ensure robust triangulation of findings. Primary interviews were conducted with a diverse set of experts, including cardiac surgeons, heart failure cardiologists, procurement directors, manufacturing executives, and clinical trialists, to capture both operational realities and strategic priorities across care settings. These qualitative insights were supplemented by a systematic review of peer-reviewed clinical studies, registry data, and device-specific post-market reports to ground device performance narratives in published evidence.

Regulatory and reimbursement landscapes were analyzed through a review of public filings, guidance documents, and payer policy statements, enabling the mapping of approval and coverage considerations across major jurisdictions. Supply chain resilience assessments incorporated supplier network analysis, trade flow data, and public disclosures to identify bottlenecks, single-source dependencies, and potential mitigants such as alternate vendors or localized production. Competitive dynamics were evaluated through patent landscaping, product launch tracking, and analysis of corporate announcements to understand strategic moves such as partnerships, licensing agreements, and manufacturing investments.

Throughout the research lifecycle, findings were iteratively validated with subject-matter experts and cross-checked against multiple information sources to reduce bias and ensure accuracy. Where gaps in public data existed, targeted expert elicitation provided contextual clarity. This methodology ensures that conclusions are grounded in a comprehensive evidence base that reflects both clinical realities and commercial imperatives.

A succinct conclusion that synthesizes how innovation, evidence generation, and operational resilience converge to determine success in mechanical circulatory support

In summary, the heart pump device sector stands at an inflection point where clinical innovation, care delivery transformation, and operational resilience must align to realize broader adoption and patient benefit. Technological progress is enabling expanded indications and new care settings, yet successful commercialization will depend on the capacity to demonstrate long-term value, manage complex supply chains, and integrate services that support patients and providers across the continuum of care. Tariff-induced pressures and regional heterogeneity underscore the importance of supply diversification and localized strategies, while segmentation insights highlight clear differences in product requirements and go-to-market tactics.

Collectively, these dynamics suggest that organizations which invest in pragmatic evidence generation, adaptive manufacturing models, and compelling lifecycle service offerings will be best positioned to lead. By focusing on both the clinical and economic narratives that matter to decision-makers, and by strengthening operational foundations to mitigate external shocks, stakeholders can convert innovation into improved patient outcomes and durable commercial returns. The conclusions drawn here provide a strategic foundation for next-step planning and targeted execution across product development, market entry, and post-market support.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Heart Pump Device Market, by Device Category

  • 8.1. Total Artificial Heart
  • 8.2. Ventricular Assist Devices
    • 8.2.1. BiVentricular Assist Devices
    • 8.2.2. Left Ventricular Assist Devices
    • 8.2.3. Right Ventricular Assist Devices

9. Heart Pump Device Market, by Application

  • 9.1. Bridge To Transplant
  • 9.2. Destination Therapy
    • 9.2.1. Adult
    • 9.2.2. Pediatric

10. Heart Pump Device Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals

11. Heart Pump Device Market, by Sales Channel

  • 11.1. Direct Sales
  • 11.2. Distributor Sales

12. Heart Pump Device Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Heart Pump Device Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Heart Pump Device Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Heart Pump Device Market

16. China Heart Pump Device Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Abiomed, Inc.
  • 17.7. Berlin Heart GmbH
  • 17.8. BiVACOR, Inc.
  • 17.9. Calon Cardio-Technology Ltd.
  • 17.10. CardiacAssist, Inc.
  • 17.11. CH Biomedical, Inc.
  • 17.12. Cirtec Medical Systems, Inc.
  • 17.13. CorWave SA
  • 17.14. Evaheart, Inc.
  • 17.15. FineHeart SA
  • 17.16. Getinge AB
  • 17.17. Jarvik Heart, Inc.
  • 17.18. Leviticus Cardio Ltd.
  • 17.19. LivaNova plc
  • 17.20. Medtronic plc
  • 17.21. NuPulseCV, Inc.
  • 17.22. ReliantHeart, Inc.
  • 17.23. SynCardia Systems, LLC
  • 17.24. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART PUMP DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HEART PUMP DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HEART PUMP DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HEART PUMP DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HEART PUMP DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEART PUMP DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS HEART PUMP DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA HEART PUMP DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. GCC HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. GCC HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. G7 HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 135. G7 HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 136. G7 HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. G7 HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NATO HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. NATO HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NATO HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HEART PUMP DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES HEART PUMP DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA HEART PUMP DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA HEART PUMP DEVICE MARKET SIZE, BY DEVICE CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA HEART PUMP DEVICE MARKET SIZE, BY VENTRICULAR ASSIST DEVICES, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA HEART PUMP DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA HEART PUMP DEVICE MARKET SIZE, BY DESTINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA HEART PUMP DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA HEART PUMP DEVICE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)